Opinion|Videos|March 17, 2025
Importance of Multidisciplinary Teams for Friedreich Ataxia Treatment and Quality of Life
Author(s)David R. Lynch, MD, PhD
An expert discusses how Friedreich ataxia significantly impacts quality of life through progressive neurological deterioration affecting mobility, coordination, and cardiovascular health. Standard care includes symptom management with physical/occupational therapy and cardiac monitoring for both pediatric and adult patients. Multidisciplinary teams (neurologists, cardiologists, therapists, and genetic counselors) coordinate comprehensive care addressing the disease's multisystem effects.
Advertisement
Video content above is prompted by the following:
- How does Friedreich ataxia impact patients’ quality of life?
- What is the standard of care for both pediatric and adult patients?
- How are multidisciplinary care teams involved in the treatment of Friedreich ataxia?
Advertisement
Related to this article
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 9, 2026.
Carmela Tartaglia, MD, FRCPC, discusses the challenges of diagnosing frontotemporal dementia, the evolving role of biomarkers, and emerging approaches to disease modification.
Catch up on any of the neurology headlines you may have missed in September 2026, compiled into 1 place by the NeurologyLive® team.
Newly announced Phase 4 THRIVE trial results showed most patients who previously had an inadequate response to a CGRP-targeting therapy improved with eptinezumab over 24 weeks.
Phase 3 ARISE trial results show solengepras 150 mg significantly reduced OFF time and improved motor and non-motor symptoms in Parkinson disease.
An MDS 2026 plenary speaker discusses the evolving role of infusion therapies, deep brain stimulation, and focused ultrasound in Parkinson disease, including when to consider device-aided therapies and how treatment selection can be individualized.
Mitzi Joi Williams, MD, is joined by Jakai McEwen, DO, and Charnetta Colton-Poole, MD, to discuss the challenges of communication between patients and their health care teams, including navigating medical language, promoting shared decision-making, and advocating for clear, patient-centered care.
Christen Kutz, PhD, PA-C, discusses a retrospective survey of neurology providers examining why patients with generalized myasthenia gravis are transitioning to nipocalimab and what real-world outcomes data suggest about its role in the treatment landscape.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Solengepras Meets Primary Endpoint in Phase 3 ARISE Trial of Parkinson Disease
2
CSF Biomarkers Identify Shared LRRK2 Pathway Activation in Sporadic and LRRK2-Associated Parkinson Disease
3
Advanced Therapies in Parkinson Disease: Matching the Right Treatment to the Right Patient
4
Frontotemporal Dementia Diagnosis, Head Impacts, and Emerging Treatment Approaches
5